Table 4.
Side Effects and outcomes of Anti-Tuberculosis Therapy in Patients
| Variable | Non-CKD (n=50) | Pre-HD (n=51) | HD (n=66) | p-value |
|---|---|---|---|---|
| Treatment outcome | ||||
| Success | 46(93.9%) | 32(68.1%)a | 37(62.7%)a | ˂0.001 |
| Died | 3(6.1%) | 15(31.9%)a | 22(37.3%)a | 0.001 |
| Side effect | ||||
| Nausea and vomiting | 4(8.2%) | 10(21.3%) | 18(30.5%)a | 0.017 |
| Abnormal liver function | 8(16.3%) | 4(8.5%) | 7(11.9%) | 0.503 |
| Central nerve damage | 4(8.2%) | 9(19.1%)a | 17(28.8%)a | 0.026 |
| Peripheral nerve damage | 2(4.1%) | 4(8.5%) | 13(22.0%)ab | 0.012 |
| Joint pain | 1(2.0%) | 2(4.3%) | 1(1.7%) | 0.701 |
| Drug allergy | 3(6.1%) | 4(8.5%) | 4(6.8%) | 0.897 |
Notes: Data are presented as frequency (%). Central nerve damage included dizziness, headache, and optic neuritis. Peripheral nerve damage included neurological symptoms of impaired sensation, movement and gland function in the hands and/or feet. ap<0.05 compared with the non-CKD group. bp<0.05 compared with the pre-CKD group.
Abbreviations: CKD, chronic kidney disease; HD, hemodialysis.